Posted by SLS on September 18, 2022, at 20:25:24
In reply to Re: To SLS, posted by Roslynn on September 17, 2022, at 16:08:56
Caplyta (lumateperone) has recently been approved for bipolar type I depression and bipolar type II depression. Its original indication was for schizophrenia. In addition to the 5-HT2a and D2 receptor antagonism that other antipsychotics demonstrate, lumateperone acts as a modulator of glutamate activity. There is some thought that low glutamate activity contributes to depression. The conundrum is always the same. Is low glutamate the cause of depression or is depression the cause of low glutamate.
If it had been available 5 years ago, I would have liked to have tried lumateperone. Latuda (lurasidone) is supposed to be for bipolar depression, too. However, I haven't come across any success stories that lead to remission.
I am curious if you have tried Abilify (aripiprazole).
- ScottSome see things as they are and ask why.
I dream of things that never were and ask why not.The only thing necessary for the triumph of evil is that good men do nothing.
poster:SLS
thread:1120673
URL: http://www.dr-bob.org/babble/20220917/msgs/1120723.html